Abstract
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing their adverse side effect profile associated with inhibition of COX-1. While COX-2 specific inhibitors have proven to be efficacious in a variety of inflammatory conditions, exposure of large numbers of patients to these drugs in postmarketing studies have uncovered potential safety concerns that raise questions about the benefit/risk ratio of COX-2-specific NSAIDs compared to conventional NSAIDs. This article reviews the efficacy and safety profiles of COX-2-specific inhibitors, comparing them with conventional NSDAIDs.
Full Text
The Full Text of this article is available as a PDF (221.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Amin A. R., Attur M., Patel R. N., Thakker G. D., Marshall P. J., Rediske J., Stuchin S. A., Patel I. R., Abramson S. B. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest. 1997 Mar 15;99(6):1231–1237. doi: 10.1172/JCI119280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Anderson G. D., Hauser S. D., McGarity K. L., Bremer M. E., Isakson P. C., Gregory S. A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996 Jun 1;97(11):2672–2679. doi: 10.1172/JCI118717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bauer M. K., Lieb K., Schulze-Osthoff K., Berger M., Gebicke-Haerter P. J., Bauer J., Fiebich B. L. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem. 1997 Feb 1;243(3):726–731. doi: 10.1111/j.1432-1033.1997.00726.x. [DOI] [PubMed] [Google Scholar]
- Beiche F., Scheuerer S., Brune K., Geisslinger G., Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 1996 Jul 22;390(2):165–169. doi: 10.1016/0014-5793(96)00604-7. [DOI] [PubMed] [Google Scholar]
- Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M. B., Hawkey C. J., Hochberg M. C. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103. [DOI] [PubMed] [Google Scholar]
- Breitner J. C., Gau B. A., Welsh K. A., Plassman B. L., McDonald W. M., Helms M. J., Anthony J. C. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994 Feb;44(2):227–232. doi: 10.1212/wnl.44.2.227. [DOI] [PubMed] [Google Scholar]
- Brideau C., Kargman S., Liu S., Dallob A. L., Ehrich E. W., Rodger I. W., Chan C. C. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res. 1996 Feb;45(2):68–74. doi: 10.1007/BF02265118. [DOI] [PubMed] [Google Scholar]
- Brune K., Graft P. Non-steroid anti-inflammatory drugs: influence of extra-cellular pH on biodistribution and pharmacological effects. Biochem Pharmacol. 1978 Feb 15;27(4):525–530. doi: 10.1016/0006-2952(78)90388-x. [DOI] [PubMed] [Google Scholar]
- Cao C., Matsumura K., Yamagata K., Watanabe Y. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res. 1995 Oct 30;697(1-2):187–196. doi: 10.1016/0006-8993(95)00839-i. [DOI] [PubMed] [Google Scholar]
- Cashman J. N. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996;52 (Suppl 5):13–23. doi: 10.2165/00003495-199600525-00004. [DOI] [PubMed] [Google Scholar]
- Catella-Lawson F., Reilly M. P., Kapoor S. C., Cucchiara A. J., DeMarco S., Tournier B., Vyas S. N., FitzGerald G. A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001 Dec 20;345(25):1809–1817. doi: 10.1056/NEJMoa003199. [DOI] [PubMed] [Google Scholar]
- Chan C. C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A. W., Forrest M. J., Gauthier J. Y. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551–560. [PubMed] [Google Scholar]
- Cheng H. F., Wang J. L., Zhang M. Z., Miyazaki Y., Ichikawa I., McKanna J. A., Harris R. C. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest. 1999 Apr;103(7):953–961. doi: 10.1172/JCI5505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Coceani F., Lees J., Bishai I. Further evidence implicating prostaglandin E2 in the genesis of pyrogen fever. Am J Physiol. 1988 Mar;254(3 Pt 2):R463–R469. doi: 10.1152/ajpregu.1988.254.3.R463. [DOI] [PubMed] [Google Scholar]
- Crofford L. J. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997 Jul;49:15–19. [PubMed] [Google Scholar]
- Cronberg S., Wallmark E., Söderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol. 1984 Aug;33(2):155–159. doi: 10.1111/j.1600-0609.1984.tb02390.x. [DOI] [PubMed] [Google Scholar]
- DeWitt D., Smith W. L. Yes, but do they still get headaches? Cell. 1995 Nov 3;83(3):345–348. doi: 10.1016/0092-8674(95)90109-4. [DOI] [PubMed] [Google Scholar]
- Distel M., Mueller C., Bluhmki E., Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1996 Apr;35 (Suppl 1):68–77. doi: 10.1093/rheumatology/35.suppl_1.68. [DOI] [PubMed] [Google Scholar]
- Dray A., Urban L. New pharmacological strategies for pain relief. Annu Rev Pharmacol Toxicol. 1996;36:253–280. doi: 10.1146/annurev.pa.36.040196.001345. [DOI] [PubMed] [Google Scholar]
- Dubois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B., Lipsky P. E. Cyclooxygenase in biology and disease. FASEB J. 1998 Sep;12(12):1063–1073. [PubMed] [Google Scholar]
- Dubois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B., Lipsky P. E. Cyclooxygenase in biology and disease. FASEB J. 1998 Sep;12(12):1063–1073. [PubMed] [Google Scholar]
- Eberhart C. E., Coffey R. J., Radhika A., Giardiello F. M., Ferrenbach S., DuBois R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994 Oct;107(4):1183–1188. doi: 10.1016/0016-5085(94)90246-1. [DOI] [PubMed] [Google Scholar]
- Feldman M., McMahon A. T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med. 2000 Jan 18;132(2):134–143. doi: 10.7326/0003-4819-132-2-200001180-00008. [DOI] [PubMed] [Google Scholar]
- Fored C. M., Ejerblad E., Lindblad P., Fryzek J. P., Dickman P. W., Signorello L. B., Lipworth L., Elinder C. G., Blot W. J., McLaughlin J. K. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med. 2001 Dec 20;345(25):1801–1808. doi: 10.1056/NEJMoa010323. [DOI] [PubMed] [Google Scholar]
- Fu J. Y., Masferrer J. L., Seibert K., Raz A., Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem. 1990 Oct 5;265(28):16737–16740. [PubMed] [Google Scholar]
- García Rodríguez L. A., Williams R., Derby L. E., Dean A. D., Jick H. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med. 1994 Feb 14;154(3):311–316. doi: 10.1001/archinte.1994.00420030117012. [DOI] [PubMed] [Google Scholar]
- Gierse J. K., Hauser S. D., Creely D. P., Koboldt C., Rangwala S. H., Isakson P. C., Seibert K. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305(Pt 2):479–484. doi: 10.1042/bj3050479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gierse J. K., Koboldt C. M., Walker M. C., Seibert K., Isakson P. C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999 May 1;339(Pt 3):607–614. [PMC free article] [PubMed] [Google Scholar]
- Henry D., Page J., Whyte I., Nanra R., Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol. 1997 Jul;44(1):85–90. doi: 10.1046/j.1365-2125.1997.00631.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ho M. L., Chang J. K., Chuang L. Y., Hsu H. K., Wang G. J. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic functions. Biochem Pharmacol. 1999 Sep 15;58(6):983–990. doi: 10.1016/s0006-2952(99)00186-0. [DOI] [PubMed] [Google Scholar]
- Jeffcoat M. K., Reddy M. S., Moreland L. W., Koopman W. J. Effects of nonsteroidal antiinflammatory drugs on bone loss in chronic inflammatory disease. Ann N Y Acad Sci. 1993 Nov 30;696:292–302. doi: 10.1111/j.1749-6632.1993.tb17164.x. [DOI] [PubMed] [Google Scholar]
- Jiang Y., Zhao J., Genant H. K., Dequeker J., Geusens P. Bone mineral density and biomechanical properties of spine and femur of ovariectomized rats treated with naproxen. Bone. 1998 May;22(5):509–514. doi: 10.1016/s8756-3282(98)00027-1. [DOI] [PubMed] [Google Scholar]
- Jones A. C., Doherty M. The treatment of osteoarthritis. Br J Clin Pharmacol. 1992 Apr;33(4):357–363. doi: 10.1111/j.1365-2125.1992.tb04052.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kang R. Y., Freire-Moar J., Sigal E., Chu C. Q. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol. 1996 Aug;35(8):711–718. doi: 10.1093/rheumatology/35.8.711. [DOI] [PubMed] [Google Scholar]
- Kaufmann W. E., Worley P. F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2317–2321. doi: 10.1073/pnas.93.6.2317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kawaguchi H., Pilbeam C. C., Harrison J. R., Raisz L. G. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res. 1995 Apr;(313):36–46. [PubMed] [Google Scholar]
- Kawamori T., Rao C. V., Seibert K., Reddy B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998 Feb 1;58(3):409–412. [PubMed] [Google Scholar]
- Kroll M. H., Hellums J. D., McIntire L. V., Schafer A. I., Moake J. L. Platelets and shear stress. Blood. 1996 Sep 1;88(5):1525–1541. [PubMed] [Google Scholar]
- Kune G. A., Kune S., Watson L. F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988 Aug 1;48(15):4399–4404. [PubMed] [Google Scholar]
- Lane N. E. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol Suppl. 1997 Jul;49:20–24. [PubMed] [Google Scholar]
- Li S., Wang Y., Matsumura K., Ballou L. R., Morham S. G., Blatteis C. M. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(-/-), but not in cyclooxygenase-1(-/-) mice. Brain Res. 1999 Apr 17;825(1-2):86–94. doi: 10.1016/s0006-8993(99)01225-1. [DOI] [PubMed] [Google Scholar]
- Loll P. J., Picot D., Garavito R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995 Aug;2(8):637–643. doi: 10.1038/nsb0895-637. [DOI] [PubMed] [Google Scholar]
- Luong C., Miller A., Barnett J., Chow J., Ramesha C., Browner M. F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol. 1996 Nov;3(11):927–933. doi: 10.1038/nsb1196-927. [DOI] [PubMed] [Google Scholar]
- Masferrer J. L., Isakson P. C., Seibert K. Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin North Am. 1996 Jun;25(2):363–372. doi: 10.1016/s0889-8553(05)70252-1. [DOI] [PubMed] [Google Scholar]
- Masferrer J. L., Zweifel B. S., Manning P. T., Hauser S. D., Leahy K. M., Smith W. G., Isakson P. C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3228–3232. doi: 10.1073/pnas.91.8.3228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Masferrer J. L., Zweifel B. S., Seibert K., Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest. 1990 Oct;86(4):1375–1379. doi: 10.1172/JCI114850. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McAdam B. F., Catella-Lawson F., Mardini I. A., Kapoor S., Lawson J. A., FitzGerald G. A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272–277. doi: 10.1073/pnas.96.1.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morrison B. W., Daniels S. E., Kotey P., Cantu N., Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol. 1999 Oct;94(4):504–508. doi: 10.1016/s0029-7844(99)00360-9. [DOI] [PubMed] [Google Scholar]
- Oshima M., Dinchuk J. E., Kargman S. L., Oshima H., Hancock B., Kwong E., Trzaskos J. M., Evans J. F., Taketo M. M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996 Nov 29;87(5):803–809. doi: 10.1016/s0092-8674(00)81988-1. [DOI] [PubMed] [Google Scholar]
- Picot D., Loll P. J., Garavito R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994 Jan 20;367(6460):243–249. doi: 10.1038/367243a0. [DOI] [PubMed] [Google Scholar]
- Rainsford K. D., Ying C., Smith F. C. Effects of meloxicam, compared with other NSAIDs, on cartilage proteoglycan metabolism, synovial prostaglandin E2, and production of interleukins 1, 6 and 8, in human and porcine explants in organ culture. J Pharm Pharmacol. 1997 Oct;49(10):991–998. doi: 10.1111/j.2042-7158.1997.tb06030.x. [DOI] [PubMed] [Google Scholar]
- Rashad S., Revell P., Hemingway A., Low F., Rainsford K., Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet. 1989 Sep 2;2(8662):519–522. doi: 10.1016/s0140-6736(89)90651-x. [DOI] [PubMed] [Google Scholar]
- Redfern J. S., Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):596–605. doi: 10.1016/s0016-5085(89)80055-1. [DOI] [PubMed] [Google Scholar]
- Rich J. B., Rasmusson D. X., Folstein M. F., Carson K. A., Kawas C., Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995 Jan;45(1):51–55. doi: 10.1212/wnl.45.1.51. [DOI] [PubMed] [Google Scholar]
- Riendeau D., Percival M. D., Brideau C., Charleson S., Dubé D., Ethier D., Falgueyret J. P., Friesen R. W., Gordon R., Greig G. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001 Feb;296(2):558–566. [PubMed] [Google Scholar]
- Rogers J., Kirby L. C., Hempelman S. R., Berry D. L., McGeer P. L., Kaszniak A. W., Zalinski J., Cofield M., Mansukhani L., Willson P. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993 Aug;43(8):1609–1611. doi: 10.1212/wnl.43.8.1609. [DOI] [PubMed] [Google Scholar]
- Saino H., Matsuyama T., Takada J., Kaku T., Ishii S. Long-term treatment of indomethacin reduces vertebral bone mass and strength in ovariectomized rats. J Bone Miner Res. 1997 Nov;12(11):1844–1850. doi: 10.1359/jbmr.1997.12.11.1844. [DOI] [PubMed] [Google Scholar]
- Schafer A. I. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med. 1999 May 31;106(5B):25S–36S. doi: 10.1016/s0002-9343(99)00114-x. [DOI] [PubMed] [Google Scholar]
- Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm. 1990;10(1):56–65. [PubMed] [Google Scholar]
- Schoen R. T., Vender R. J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med. 1989 Apr;86(4):449–458. doi: 10.1016/0002-9343(89)90344-6. [DOI] [PubMed] [Google Scholar]
- Schwartz J. I., Chan C. C., Mukhopadhyay S., McBride K. J., Jones T. M., Adcock S., Moritz C., Hedges J., Grasing K., Dobratz D. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. Clin Pharmacol Ther. 1999 Jun;65(6):653–660. doi: 10.1016/S0009-9236(99)90087-5. [DOI] [PubMed] [Google Scholar]
- Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12013–12017. doi: 10.1073/pnas.91.25.12013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Silverstein F. E., Faich G., Goldstein J. L., Simon L. S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N. M., Stenson W. F. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247–1255. doi: 10.1001/jama.284.10.1247. [DOI] [PubMed] [Google Scholar]
- Smalley W. E., DuBois R. N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol. 1997;39:1–20. doi: 10.1016/s1054-3589(08)60067-8. [DOI] [PubMed] [Google Scholar]
- Smith C. J., Zhang Y., Koboldt C. M., Muhammad J., Zweifel B. S., Shaffer A., Talley J. J., Masferrer J. L., Seibert K., Isakson P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313–13318. doi: 10.1073/pnas.95.22.13313. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stewart W. F., Kawas C., Corrada M., Metter E. J. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997 Mar;48(3):626–632. doi: 10.1212/wnl.48.3.626. [DOI] [PubMed] [Google Scholar]
- Thun M. J., Namboodiri M. M., Heath C. W., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. doi: 10.1056/NEJM199112053252301. [DOI] [PubMed] [Google Scholar]
- Thun M. J., Namboodiri M. M., Heath C. W., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. doi: 10.1056/NEJM199112053252301. [DOI] [PubMed] [Google Scholar]
- Vane J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232–235. doi: 10.1038/newbio231232a0. [DOI] [PubMed] [Google Scholar]
- Waddell W. R., Ganser G. F., Cerise E. J., Loughry R. W. Sulindac for polyposis of the colon. Am J Surg. 1989 Jan;157(1):175–179. doi: 10.1016/0002-9610(89)90442-x. [DOI] [PubMed] [Google Scholar]
- White William B., Faich Gerald, Whelton Andrew, Maurath Clement, Ridge Nancy J., Verburg Kenneth M., Geis G. Steven, Lefkowith James B. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002 Feb 15;89(4):425–430. doi: 10.1016/s0002-9149(01)02265-2. [DOI] [PubMed] [Google Scholar]
- Willingale H. L., Gardiner N. J., McLymont N., Giblett S., Grubb B. D. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol. 1997 Dec;122(8):1593–1604. doi: 10.1038/sj.bjp.0701548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Woodiel F. N., Fall P. M., Raisz L. G. Anabolic effects of prostaglandins in cultured fetal rat calvariae: structure-activity relations and signal transduction pathway. J Bone Miner Res. 1996 Sep;11(9):1249–1255. doi: 10.1002/jbmr.5650110909. [DOI] [PubMed] [Google Scholar]
- Yamagata K., Andreasson K. I., Kaufmann W. E., Barnes C. A., Worley P. F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993 Aug;11(2):371–386. doi: 10.1016/0896-6273(93)90192-t. [DOI] [PubMed] [Google Scholar]
- Yamamoto T., Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Res. 1996 Nov 11;739(1-2):104–110. doi: 10.1016/s0006-8993(96)00817-7. [DOI] [PubMed] [Google Scholar]
- Zhang F., Subbaramaiah K., Altorki N., Dannenberg A. J. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem. 1998 Jan 23;273(4):2424–2428. doi: 10.1074/jbc.273.4.2424. [DOI] [PubMed] [Google Scholar]
- Zhao S. Z., Reynolds M. W., Lejkowith J., Whelton A., Arellano F. M. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther. 2001 Sep;23(9):1478–1491. doi: 10.1016/s0149-2918(01)80121-1. [DOI] [PubMed] [Google Scholar]
- del Rincón I. D., Williams K., Stern M. P., Freeman G. L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001 Dec;44(12):2737–2745. doi: 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-%23. [DOI] [PubMed] [Google Scholar]
- in t' Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., Breteler M. M., Stricker B. H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001 Nov 22;345(21):1515–1521. doi: 10.1056/NEJMoa010178. [DOI] [PubMed] [Google Scholar]